Doxofylline 400mg Tablet (DOXOLLIN) 100s

665.00

Out of stock

SKU: 06052020013115 Category:

Description

Indications

Listed in Dosage.

Dosage

Adult : PO Reversible airways obstruction; COPD 400 mg bid-tid.

Dosage Details

Oral
COPD (chronic obstructive pulmonary disease), Reversible airways obstruction

Adult: 400 mg bid-tid. Max: 1,200 mg daily.
Child: <12 years 6-9 mg/kg bid; >12 years Same as adult dose.
Elderly: 200 mg bid-tid.

Contraindications

Acute MI, hypotension. Lactation.

Special Precautions

Patients with cardiac disease (e.g. cardiac arrhythmias, angina pectoris, CHF, acute myocardial injury, hypertension), peptic ulcer, hyperthyroidism, hypoxemia, chronic cor pulmonale, convulsive disorder. Hepatic and renal impairment. Children and elderly. Pregnancy.

Adverse Drug Reactions

Cardiac disorders: Tachycardia, palpitation, extrasystole.
Metabolism and nutrition disorders: Hyperglycaemia.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain, epigastric pain.
General disorders and administration site disorders: Irritability.
Nervous system disorders: Headache, nervousness, dizziness.
Psychiatric disorders: Insomnia, nervousness.
Renal and urinary disorders: Albuminuria.

Overdosage

Symptoms: Nausea, vomiting, gastroinstestinal bleeding, metabolic acidosis, hypokalaemia, hypotension, cardiac arrythmias, and seizures. Management: Symptomatic and supportive treatment. May induce emesis or perform gastric lavage followed by administration of activated charcoal and cathartic. Establish adequate airway. IV diazepam and/or phenobarbital may be given in cases of seizure.

Drug Interactions

Decreased xanthine clearance with cimetidine, allopurinol, propranolol, antibiotics (e.g. erythromycin, lincomycin, ciprofloxacin) and anti-flu vaccine. Increased xanthine clearance with anticonvulsants (e.g. phenytoin). May potentiate hypokalaemia with β2- agonist.

Mechanism of Action

Description: Doxophylline is a methylxanthine derivative that possesses potent bronchodilator activity by inhibiting phosphodiesterase enzymes followed by an increase in cyclic-3’, 5’ adenosine monophosphate (cAMP) resulting in smooth muscle relaxation.
Pharmacokinetics:
Absorption: Absolute bioavailability: Approx 62.6%. Time to peak plasma concentration: 30-60 minutes.
Distribution: Volume of distribution: Approx 1 L/kg. Plasma protein binding: Approx 48%.
Excretion: Via urine (< 4% as unchanged drug). Elimination half-lie: >6 hours.

Storage

Store below 30°C.

MIMS Class

Antiasthmatic & COPD Preparations

ATC Classification

R03DA11 – doxofylline ; Belongs to the class of xanthines. Used in the systemic treatment of obstructive airway diseases.

Additional information

location

davao, cdo, dipolog, butuan